Pertuzumab + Trastuzumab + eribulin
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-positive Breast Cancer
Conditions
HER2-positive Breast Cancer, Metastatic Breast Cancer
Trial Timeline
Sep 1, 2013 → Dec 1, 2016
NCT ID
NCT01912963About Pertuzumab + Trastuzumab + eribulin
Pertuzumab + Trastuzumab + eribulin is a phase 2 stage product being developed by Eisai for HER2-positive Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01912963. Target conditions include HER2-positive Breast Cancer, Metastatic Breast Cancer.
What happened to similar drugs?
0 of 15 similar drugs in HER2-positive Breast Cancer were approved
Approved (0) Terminated (0) Active (15)
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01912963 | Phase 2 | Terminated |
Competing Products
20 competing products in HER2-positive Breast Cancer